Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK

IF 2.9 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of Medical Economics Pub Date : 2024-04-09 DOI:10.1080/13696998.2024.2340932

Karissa Johnston, Lauren C Powell, Evan Popoff, Gil J L’Italien, Robert Pawinski, Aideen Ahern, Sam Large, Thang Tran, Aaron Jenkins

引用次数: 0

Abstract

Migraine is the most common disabling headache disorder and is characterized by recurrent throbbing head pain and symptoms of photophobia, phonophobia, nausea, and vomiting. Rimegepant 75mg, an ora...

查看原文本刊更多论文

在英国，在偏头痛的急性期治疗中，利美喷口服冻干粉与最佳支持性护理的成本效益比较

偏头痛是最常见的致残性头痛疾病，其特征是反复发作的头部搏动性疼痛以及畏光、畏声、恶心和呕吐症状。Rimegepant 75 毫克是一种抗偏头痛药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Economics HEALTH CARE SCIENCES & SERVICES-MEDICINE, GENERAL & INTERNAL

CiteScore

4.50

自引率

4.20%

发文量

122

期刊介绍： Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication. Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience